The genetics of vascular complications in diabetes mellitus.
Prospective identification of which individuals with diabetes mellitus (DM) are at greatest risk for developing cardiovascular disease (CVD) complications would have considerable public health importance by allowing the allocation of limited resources to be focused on those individuals who would most benefit from aggressive intervention. Over the past 20 years genetic disease association studies have demonstrated that polymorphisms at specific genetic loci may identify those individuals at greatest risk for developing CVD in the setting of DM. This article reviews the evidence accumulated to date on four polymorphic loci with the aim of explaining how these polymorphisms modify the risk for CVD in DM by modifying the functional activity of a specific gene. Use of the knowledge of these genetic differences among individuals in targeting drug therapy (pharmacogenomics) is also discussed.
Farbstein
Dan
D
Technion-Israel Institute of Technology, Haifa, Israel. dfarb@tx.technion.ac.il
Levy
Andrew P
AP
D043303:Aryldialkylphosphatase / Q000235:genetics; D001808:Blood Vessels / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000235:genetics*; D006242:Haptoglobins / Q000235:genetics / Q000378:metabolism; D006710:Homocysteine / Q000378:metabolism; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000378:metabolism; D018384:Oxidative Stress; D011110:Polymorphism, Genetic; D012189:Retrospective Studies
D006242:Haptoglobins; D006710:Homocysteine; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D043303:Aryldialkylphosphatase